Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer
Bladder cancer (BCa) is a common urological malignancy with a high recurrence rate, often within 2 years of initial diagnosis and treatment. Due to this high recurrence, near all patients require cystoscopic surveillance, which is invasive, uncomfortable, and costly. The cost of surveillance makes t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co. Ltd.
2025-01-01
|
| Series: | Advances in Biomarker Sciences and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2543106425000110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|